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Abstract
Although lithium remains the preferred medication for bipolar disorders, new
investigations suggest that only 60 to 80% of patients have a good response
with a classical presentation. The antiepileptics carbamazepine and valproate
are important alternatives. Several studies have shown that lithium, carbam-
azepine and valproate are effective in pure mania. Mixed mania and rapid
cycling respond, however, well to valproate. One disadvantage of carbamaze-
pine is its enzyme inducing property with the consequence of a decrease of
plasma levels of other psychotropic medications and a worsening of psycho-
pathology. First data indicate a good antimanic and antidepressive efficacy
of the new antiepileptic drug lamotrigine.
.......................
Introduction increased activity. Approximately 40–60% of manic pa-
tients suffer from this type of mania. Up to 50% of bipolar
patients, however, have mixed (or dysphoric mania) whichThere is now substantial evidence that the mood stabi-
lizers lithium, carbamazepine and valproate are effective is defined as an episode meeting the criteria both for
mania and for a major depressive phase. Several investi-in the treatment of acute episodes of mania. Less study
data exist for the efficacy of these mood stabilizers in the gations indicate that lithium, carbamazepine and valpro-
ate are effective in pure mania. On the other hand, thesemanagement of bipolar (and unipolar) depression and in
the prophylaxis of depressive phases [1–4]. The knowledge results also establish that mixed mania responds well to
valproate whereas lithium is relatively ineffective in mixedof several predictors of response for the different mood
stabilizers would improve the total treatment response mania [1, 6–8] (table 1).
A recently completed study from the European valpro-and eventually shorten the duration of hospitalization
for the patients [5]. ate acute mania study group [9] corroborates the results
of the other cited studies. The aim of that investigation
was to show that valproate-treated patients need less neu-
roleptics than placebo-treated patients. 136 patients werePure Mania vs. Mixed Mania
enrolled in this multicenter, randomized, double-blind,
placebo-controlled parallel group study. As a result thePure (or euphoric or typical) mania is characterized
by typical manic symptoms without depressive features, mean daily dose of concomitant neuroleptic medication
expressed as mg haloperidol equivalents continuously de-e.g. elevated mood, grandiosity, reduced sleep time and
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Table 1. Predictors of good response to valproate
Mixed mania Himmelhoch et al. (1976) 41% moderate or better response for lithium in mixed mania
vs. 81% in pure mania
Secunda et al. (1985) 29% moderate or better response for lithium in mixed mania
vs. 91% in pure mania
Prien et al. (1988) 36% moderate or better response for lithium in mixed mania
vs. 59% in pure mania
Mu¨ller-Oerlinghausen et al. decrease of haloperidol equivalents in the total
and European valproate acute valproate group from 14.3 to 8.1 mg and for dysphoria item
mania study group (1997) from 13.9 to 5.8 mg
Swann et al. (1997) a depressive presentation was associated with a poorer
response to lithium in several scales (SADS)
Rapid cycling Dunner and Fieve (1974) 82% of rapid cyclers were Li-resistant vs. 41% in the group
of classical mania
Kukopulos et al. (1980) open longitudinal study; 72% show low efficacy to lithium
Calabrese et al. (1993) 101 patients with rapid cycling: marked acute and
prophylactic antimanic effects, marked antimixed
state effects and poor-to-moderate acute and prophylactic
antidepressant effects
creased in the valproate group from 14.3 mg at the begin- valproate [12, 13]. As a result the use of carbamazepine
was associated with significant lower haloperidol plasmaning of the study to 8.1 mg after 3 weeks. In the placebo
group the decline was from 12.0 mg to 10.8 mg (the levels and a worse clinical outcome (pPANSS-Score) com-
pared to antipsychotic monotherapy (fig. 2). Valproatedifference was statistically significant, p>0.0001; fig. 1).
Patients scoring high for the dysphoria item (item 5) of had no significant effect on the plasma level and did not
influence the psychopathology.the Young mania rating scale had an even more favorable
outcome with valproate, with a decrease of the daily halo-
peridol equivalents from 13.9 at the beginning to 6.1 at
the end of the study. Rapid Cycling
Another new parallel-group, double-blind study with
179 patients indicates that depressive symptoms during Four or more depressive or manic phases in 1 year
has been defined as rapid cycling bipolar disorder. It isa manic episode were associated with a poor antimanic
response to lithium and with a better response to val- assumed that 13–20% of bipolar patients have rapid cyc-
ling [16]. In general, patients with bipolar rapid cyclingproate [11]. The authors conclude that even a modest
level of pretreatment depression-related symptoms is a have a lower response rate to lithium during both acute
and prophylactic treatment [14, 15]. In an open longitu-robust predictor of lithium nonresponse and is associ-
ated with a better response to valproate. Data concern- dinal study with 434 patients 72% showed a low efficacy
of lithium treatment [17].ing carbamazepine in pure or mixed mania are less clear
because many of the clinical studies were not double Studies are not consistent concerning the efficacy of
carbamazepine in rapid cycling [18, 19]. A metaanalyisblind or randomized which limits its interpretability
[10]. shows, however, that the response rate for carbamazepine
is 32% for depression and 52% for mania which is worseA major disadvantage of carbamazepine is, however,
its enzyme-inducing properties with the consequence that than the efficacy in a prospective study indicating a good
effect for valproate in 42% of depressed and 73% of manicits own plasma levels (autoinduction) as well as plasma
levels of concomitant psychotropic medication (heteroin- patients [16]. In summary, rapid cycling seems to be a
likely predictor of less response to lithium and possiblyduction) may decrease. In a recent controlled clinical trial
with 30 patients with schizophrenia or schizoaffective carbamazepine compared to valproate.
A special problem is a possible drug-induced switchingdisorder three different groups were randomly assigned
to 4 weeks of treatment with either haloperidol alone, from bipolar depression into mania. Whereas there are
some discussions concerning a drug-induced switch intohaloperidol with carbamazepine or with haloperidol with
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Fig. 1. Decrease of the mean daily dose of haloperidol equivalents
in the valproate group and the placebo group. According to Mu¨ller-
Oerlinghausen and Retzow and the European valproate acute mania
study group (1997) [9].
mania some hints in the literature indicate a cycle accel-
eration by the usage of antidepressant drugs [20].
]
In summary, the studies so far suggest that valproate
is useful in a broad spectrum of bipolar disorders and is Fig. 2. Mean rating scores of the positive subscale of the PANSS
equally effective in pure mania as well as in mixed mania in the haloperidol monotherapy group, the haloperidol+ carbam-
azepine group (CBZ) and the haloperidol+valproate group (VPA).and rapid cycling. Furthermore, all atypical types of
According to Normann et al. [13].mania, e.g. mixed mania, rapid cycling, neurological co-
factors and organic mania, respond less well to lithium.
A major advantage of valproate is the fact that the drug
Furthermore, lamotrigine also appears to be valuable in
is well tolerated in an effective plasma level range from
the prophylaxis of schizoaffective disorders [Erfurth et al.,
50 to 125 lg/ml [21]. Moreover, a dose loading with initial
this issue].
oral doses of 20 mg/kg body weight has shown a rapid
Moreover, recent single case reports suggest that gaba-
clinical improvement of psychopathology [22].
pentin might also be useful in the treatment of mania.
In an open trial we treated 14 patients with acute mania
with gabapentin in a dose range from 1,200 to 4,800
Lamotrigine and Gabapentin
mg/day [25]. Six patients received gabapentin as add-on
medication and 8 were treated with gabapentin alone. As
Several open studies suggest an efficacy of the new
a result, gabapentin was both effective and safe when
antiepileptic drug lamotrigine not only in the treatment
administered in combination with other drugs as lithium
of mania but also in depressed states in bipolar patients
or valproate. BRMAS scores decreased from 37.7 to 7.8
[23, 24]. Controlled double-blind studies are still ongoing.
on day 21 in the add-on group and from 27.8 to 9.0
Concerning long-term prophylactic efficacy, an interest-
in the monotherapy group. Four of 8 patients in the
ing case of a patient with bipolar rapid cycling with
monotherapy group dropped out due to a failure of effi-
valproate treatment reveals a drastic improvement after
cacy. As these were the patients with the highest BRMAS
the addition of lamotrigine [24]. In this case lamotrigine
scores, it can be assumed that gabapentin might be useful
up to 150 mg/day was added to valproate (2,700 mg/day).
in patients with modest but not severe mania.
A considerable improvement of the patient’s condition
was achieved several days after the beginning of lamotri-
gine coadministration and lasted over the total follow-
Aknowledgement
up period of more than 1 year. There is also increasing
evidence of the prophylactic efficacy of lamotrigine mono- The authors acknowledge support of the Theodore and Vada
Stanley Foundation.therapy in bipolar disorder with or without rapid cycling.
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